e-therapeutics plc
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and automated evaluation; and GalOmic, a proprietary siRNA chemistry that generates potent and long-acting RNAi medicines. Its preclinical products are ETX-312 to trea… Read more
e-therapeutics plc (ETXPF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of July 2024: -0.173x
Based on the latest financial reports, e-therapeutics plc (ETXPF) has a cash flow conversion efficiency ratio of -0.173x as of July 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.74 Million) by net assets ($44.66 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
e-therapeutics plc - Cash Flow Conversion Efficiency Trend (2007–2024)
This chart illustrates how e-therapeutics plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
e-therapeutics plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of e-therapeutics plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Marmota Ltd
AU:MEU
|
-0.010x |
|
TAM JAI INTERNATIONAL CO.
F:29S
|
N/A |
|
IDREAMSKY TE+H. DL-0001
F:08IA
|
N/A |
|
River Valley Community Bancorp
PINK:RVCB
|
N/A |
|
Niching Industrial
TWO:3444
|
0.087x |
|
FELIX Gold Ltd
AU:FXG
|
-0.011x |
|
Guardian Metal Resources PLC
OTCQX:GMTLF
|
N/A |
|
Bulten AB
ST:BULTEN
|
0.027x |
Annual Cash Flow Conversion Efficiency for e-therapeutics plc (2007–2024)
The table below shows the annual cash flow conversion efficiency of e-therapeutics plc from 2007 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-01-31 | $21.99 Million | $-10.90 Million | -0.495x | -104.38% |
| 2023-01-31 | $33.04 Million | $-8.01 Million | -0.242x | +13.25% |
| 2022-01-31 | $37.28 Million | $-10.42 Million | -0.279x | -16.13% |
| 2021-01-31 | $19.07 Million | $-4.59 Million | -0.241x | +46.16% |
| 2020-01-31 | $5.93 Million | $-2.65 Million | -0.447x | +17.30% |
| 2019-01-31 | $8.95 Million | $-4.84 Million | -0.540x | -34.36% |
| 2018-01-31 | $15.27 Million | $-6.14 Million | -0.402x | +30.45% |
| 2017-01-31 | $20.10 Million | $-11.63 Million | -0.578x | -85.84% |
| 2016-01-31 | $40.33 Million | $-12.55 Million | -0.311x | -16.92% |
| 2015-01-31 | $37.02 Million | $-9.86 Million | -0.266x | -107.63% |
| 2014-01-31 | $44.62 Million | $-5.72 Million | -0.128x | +67.42% |
| 2013-01-31 | $10.58 Million | $-4.16 Million | -0.393x | -78.98% |
| 2012-01-31 | $14.72 Million | $-3.24 Million | -0.220x | +96.87% |
| 2011-01-31 | $273.00K | $-1.92 Million | -7.015x | -880.79% |
| 2010-01-31 | $2.49 Million | $-1.78 Million | -0.715x | +55.93% |
| 2009-01-31 | $947.00K | $-1.54 Million | -1.623x | -80.50% |
| 2008-01-31 | $2.49 Million | $-2.24 Million | -0.899x | +72.36% |
| 2007-01-31 | $324.00K | $-1.05 Million | -3.253x | -- |